Abstract
who took finasteride experienced a 24% reduction in prostate cancer incidence compared with men taking placebo (Thompson IM et al. N Engl J Med. 2003;349[3]:215-224). Preliminary results presented earlier this year from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial indicate that dutasteride reduces the incidence of prostate cancer in men older than age 50 years by 23% compared with placebo. “Current studies are attempting to define what population of men would most benefit from these cancer preventive drugs,” said Brown. Brown noted that because clinicians still lack a thorough understanding of individuals’ susceptibility to cancer and their response to various agents, they cannot properly screen populations or predict who will benefit from different drugs. “Future preclinical and clinical studies should focus on developing accurate cancer risk assessment tools and testing next-generation targeted agents singly and in combination for their toxicity and ability to prevent cancer,” he said.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.